Cervical Cancer: HPV, Screening and Treatment

Cervical cancer is the fourth most common cancer in women worldwide, with approximately 660,000 new cases and 350,000 deaths annually. It remains a leading cause of cancer death in low- and middle-income countries where screening programmes are inadequate. In China, cervical cancer is the second most common gynaecological cancer, with approximately 120,000 new cases annually — though incidence is declining as HPV vaccination and cervical screening programmes expand.

Cervical cancer is unique among major cancers in having a well-defined, detectable pre-malignant phase (cervical intraepithelial neoplasia — CIN) lasting years to decades before progression to invasive cancer, and in being almost entirely caused by a single preventable infection: human papillomavirus (HPV). This makes cervical cancer the most preventable major cancer — through vaccination and screening, the vast majority of cases are entirely avoidable.

HPV — The Cause of Cervical Cancer

Human papillomavirus (HPV) is a double-stranded DNA virus with over 200 subtypes. Genital HPV infection is the most common sexually transmitted infection worldwide — approximately 80% of sexually active individuals will be infected at some point in their lifetime.

High-risk HPV types (oncogenic) — capable of causing cervical cancer:

• HPV 16 and 18: responsible for approximately 70% of all cervical cancers worldwide
• Other high-risk types (31, 33, 45, 52, 58): responsible for a further 20%

Low-risk HPV types (non-oncogenic): HPV 6 and 11 cause genital warts but do not cause cervical cancer.

Most HPV infections are transient — the immune system clears them within 1–2 years. Persistent infection with a high-risk HPV type (present for >12–18 months) drives transformation of the cervical squamocolumnar junction (transformation zone) → cervical intraepithelial neoplasia (CIN) → invasive cancer. This progression typically takes 10–20 years, providing an extended window for detection and treatment.

Cervical Intraepithelial Neoplasia (CIN — Pre-Cancer)

CIN is graded by the depth of epithelial involvement:

Grade	Description	Progression to Cancer	Management
CIN 1	Mild dysplasia; lower third of epithelium	~1% progress to cancer; 60% regress spontaneously	Active surveillance (repeat colposcopy/cytology)
CIN 2	Moderate dysplasia; lower two-thirds	~5% progress; 40% regress	Treatment usually recommended (LLETZ)
CIN 3	Severe dysplasia / carcinoma in situ; full thickness	~12% progress if untreated	Treatment mandatory (LLETZ)

Risk Factors

• Sexual behaviour: earlier age of first intercourse, multiple sexual partners — both increase HPV exposure risk
• Persistent high-risk HPV infection — the essential cause
• Smoking — cofactor that impairs local cervical immune clearance of HPV; doubles risk of progression from CIN to cancer
• Immunosuppression — HIV infection markedly increases risk and accelerates progression; organ transplant recipients; long-term steroids
• Long-term oral contraceptive pill (>5 years) — modest association; biological mechanism unclear
• High parity — multiple pregnancies; possibly hormonal or immune-related
• Lack of cervical screening — the dominant preventable risk factor in developed countries; most invasive cervical cancers occur in women who have never been screened

HPV Vaccination — Primary Prevention

HPV vaccination is the most impactful cervical cancer prevention measure. Three vaccines are available:

• Gardasil 9 (9-valent): targets HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 — covers >90% of cervical cancer-causing types; the current standard
• Gardasil (4-valent): HPV 6, 11, 16, 18
• Cervarix (bivalent): HPV 16, 18; cross-protection against 31, 33, 45

Timing: maximum efficacy when given before first sexual exposure (age 9–13 as primary target); effective and recommended up to age 26 routinely; may be given up to age 45 with individual decision-making. Does not protect against infections already acquired.

In China, domestic HPV vaccines (Cecolin — bivalent; Walrinvax — 9-valent) are approved alongside imported Gardasil 9. The 9-valent vaccine is now widely available in China at both public vaccination centres and private hospitals.

Evidence: Countries with high-coverage adolescent HPV vaccination programmes (Australia, UK, Scandinavia) are already observing >80% reduction in CIN2+ and dramatic declines in invasive cervical cancer incidence in vaccinated cohorts.

Cervical Screening

Despite vaccination, screening remains essential — vaccines don't protect against all HPV types, and women vaccinated as adults may have been exposed before vaccination.

Pap Smear (Cervical Cytology)

A spatula or brush collects cells from the transformation zone; prepared as a liquid-based cytology (LBC) sample. The result is reported using the Bethesda System:

• NILM (Negative for Intraepithelial Lesion or Malignancy) — normal
• ASC-US (Atypical Squamous Cells of Undetermined Significance) — reflex HPV testing
• LSIL (Low-grade Squamous Intraepithelial Lesion) — correlates with CIN 1
• HSIL (High-grade Squamous Intraepithelial Lesion) — correlates with CIN 2–3; urgent colposcopy
• ASC-H — atypical cells where HSIL cannot be excluded
• AGC (Atypical Glandular Cells) — may indicate adenocarcinoma in situ or endocervical/endometrial pathology

HPV Co-testing / Primary HPV Testing

HPV testing detects the presence of high-risk HPV DNA. Primary HPV screening (with or without cytology) is now the preferred modality in most guidelines for women over 25–30 due to higher sensitivity for CIN2+:

• HPV negative: very low risk; 3–5-year intervals between screens
• HPV positive, cytology negative: 12-month repeat co-test or colposcopy
• HPV 16/18 positive: immediate colposcopy regardless of cytology (highest risk)

China screening guidelines: population-based cervical cancer screening expanded significantly — combination HPV + cytology co-testing is increasingly available; screening target for women aged 35–64.

Colposcopy and Biopsy

Colposcopy is the investigation of abnormal smear or HPV results. A colposcope (binocular microscope) provides magnified visualisation of the cervix after application of acetic acid (acetowhite change identifies abnormal areas) and Lugol's iodine (iodine-negative areas are suspicious). Targeted biopsies are taken from abnormal-appearing areas.

Colposcopic findings are graded by density of acetowhite change, margin sharpness, and vascular patterns (punctation, mosaic, atypical vessels).

Results guide management: normal colposcopy → return to screening; CIN 1 → surveillance; CIN 2–3 → treatment; invasive cancer → oncology referral.

Symptoms of Invasive Cervical Cancer

Early-stage cervical cancer is often asymptomatic — another reason screening is essential.

Symptoms of invasive disease:

• Abnormal vaginal bleeding — the most common symptom; postcoital bleeding (after sex) is the classic presentation; intermenstrual bleeding; postmenopausal bleeding
• Vaginal discharge — watery, mucoid, or blood-stained; may be malodorous (necrotic tumour)
• Pelvic pain — as tumour invades surrounding structures
• Haematuria or rectal bleeding — tumour invasion of bladder or rectum (advanced disease)
• Leg swelling — lymphoedema from pelvic lymph node involvement
• Ureteric obstruction — renal impairment with bilateral ureteric compression in advanced disease

Staging (FIGO 2018)

Stage	Description	5-Year Survival
IA	Microscopic invasion; depth ≤5 mm	~99%
IB	Clinically visible; confined to cervix	80–90%
IIA	Invades upper vagina	70–80%
IIB	Invades parametrium	65–75%
IIIA	Invades lower vagina	40–50%
IIIB	Invades pelvic wall / hydronephrosis	35–45%
IIIC	Lymph node involvement (pelvic IIIC1; para-aortic IIIC2)	30–50%
IVA	Invades bladder/rectum	15–25%
IVB	Distant metastasis	<10%

Staging investigations: MRI pelvis (parametrial and nodal assessment, most important); CT chest/abdomen/pelvis (distant metastases); PET-CT (lymph node involvement, most sensitive).

Treatment

Treatment of Pre-Cancer (CIN 2–3)

LLETZ (Large Loop Excision of the Transformation Zone) — also called LEEP (Loop Electrosurgical Excision Procedure). An electrically heated wire loop excises the transformation zone and CIN under local anaesthesia as an outpatient procedure. Provides both diagnosis (histological assessment of excision margins) and treatment.

• Cure rate for CIN 2–3: approximately 90–95%
• Follow-up: HPV test at 6 months; if negative, return to routine screening; if positive, repeat colposcopy
• Risk of pre-term birth in subsequent pregnancy — LLETZ removes cervical stroma; large excisions or repeat LLETZ carry a small increased risk of cervical incompetence

Cryotherapy / laser ablation — alternatives for CIN 1–2 in carefully selected cases (fully visible lesion, no glandular involvement); ablative rather than excisional — no histological specimen.

Cone biopsy (cold knife cone) — for adenocarcinoma in situ, glandular lesions, or large-volume CIN where LLETZ may not achieve clear margins; performed under general anaesthesia.

Stage IA1 (Micro-invasive) — Fertility-Preserving Options

• LLETZ or cone biopsy — curative for stage IA1 with clear margins; no lymph node involvement required
• Simple hysterectomy — for women who have completed childbearing

Stage IA2–IB1 — Early Localised Disease

Radical hysterectomy (Wertheim's hysterectomy) with pelvic lymph node dissection — removes the uterus, cervix, upper vagina, parametria, and pelvic lymph nodes. The surgical standard for fit patients with stage IA2–IB1 disease.

• Robotic or laparoscopic approach: LACC trial (2018) demonstrated inferior survival with minimally invasive radical hysterectomy vs open surgery — open radical hysterectomy is now the standard approach for invasive cervical cancer
• Radical trachelectomy — removes the cervix and parametria but preserves the uterine body, allowing future pregnancy; for carefully selected stage IA2–IB1 women desiring fertility preservation; available at specialist gynaecological oncology centres

Stage IB2–IVA — Locally Advanced Disease

Concurrent cisplatin-based chemoradiotherapy (CRT) — the standard treatment; external beam radiotherapy (EBRT) to the pelvis + weekly cisplatin chemotherapy (radiosensitiser) + intracavitary brachytherapy boost to the cervix/uterus.

• Brachytherapy — radioactive source placed directly within the cervix/uterus (intracavitary) via applicators under imaging guidance; delivers high-dose conformal radiation to the tumour while limiting dose to bladder and rectum; essential component of curative radiotherapy
• Image-guided adaptive brachytherapy (IGABT) — using MRI to plan individualised brachytherapy; modern standard; superior tumour control and lower toxicity vs conventional brachytherapy

5-year survival with CRT: approximately 65–75% for stage IIB; 45–55% for stage IIIB.

Recurrent and Metastatic Cervical Cancer

Pelvic exenteration — radical surgery removing the bladder, rectum, and all pelvic organs in selected patients with central pelvic recurrence without distant metastasis; potentially curative in carefully selected patients.

Pembrolizumab + cisplatin/carboplatin + paclitaxel + bevacizumab (KEYNOTE-826): addition of pembrolizumab to standard chemotherapy improved overall survival (24.4 vs 16.5 months in PD-L1 CPS ≥1 patients) — now standard first-line for recurrent/metastatic cervical cancer.

Tisotumab vedotin (antibody-drug conjugate targeting Tissue Factor) — second-line; approved for recurrent/metastatic disease after chemotherapy.

Cervical Cancer Care in China

China's gynaecological oncology centres offer:

• HPV vaccination: Gardasil 9 (9-valent) and domestic vaccines widely available; walk-in vaccination at vaccination centres
• Cervical screening: HPV testing and liquid-based cytology (co-testing); colposcopy following an abnormal result
• LLETZ / cone biopsy for CIN: outpatient treatment of pre-cancer with histological confirmation; specialist gynaecology clinics
• Open radical hysterectomy for early cervical cancer: experienced gynaecological oncology surgeons at major centres; sentinel lymph node biopsy available
• Radical trachelectomy: fertility-preserving surgery at specialist centres for carefully selected early-stage patients
• Image-guided brachytherapy: IGABT programmes at major radiation oncology centres — the modern standard for radical radiotherapy
• Immunotherapy access: pembrolizumab-containing regimens for recurrent/metastatic disease at oncology centres; domestic biosimilar PD-1 inhibitors available
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from HPV vaccination and screening through colposcopy, surgical treatment, and chemoradiotherapy

Contact a ChinaMedicalTour care navigator to arrange HPV vaccination, cervical screening, colposcopy, or cervical cancer treatment.

---

Medical content based on MSD Manuals and international cervical cancer guidelines (ESGO, FIGO, NCCN). Evidence reviewed 2025.

Frequently Asked Questions

Can foreign patients submit pelvic imaging and gynecology reports for specialist review?

Yes. Pelvic MRI scans, transvaginal ultrasound reports, and histopathology results can be submitted for remote pre-consultation review by experienced Chinese gynecologists.

What surgical and minimally invasive treatments are offered for gynecological conditions in China?

Chinese centers evaluate laparoscopic and hysteroscopic myomectomy, excision of endometriosis, uterine artery embolization, and fertility-preserving surgical interventions.

How is care navigation handled for international gynecological patients?

China Medical Tour provides non-clinical coordination including appointment booking, on-site hospital escort, translation assistance, and certified medical documentation upon completion.